Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 256

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 256
---
     |                     — |     | (3,762 | ) |
| Recognition in equity of Common stock subject to possible redemption |     |                                |     — |     |                     — |     |      6,269 |   |     |                     — |     |      3,134 |   |     |                     — |     |      — |   |
| Total book value of net assets/(liabilities) acquired                |     |                                |     — |     |                     — |     |     (3,664 | ) |     |                     — |     |     (6,799 | ) |     |                     — |     | (9,933 | ) |
| Excess of fair value over book value                                 |     |                                |     — |     |                     — |     |     61,917 |   |     |                     — |     |     61,917 |   |     |                     — |     | 61,917 |   |

____________ Notes:- (i)Per share value based on closing prices as of December 31, 2024 for SPAC Class A common shares. (ii)See Note (3) under “ Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of December 31 , 2024.”. Incremental transaction costs correspond to those expenses for which no liabilities were recognized in APx’s historical statement of financial position as of December 31, 2024. This charge was recognized in the “Other operating results” line of the Unaudited Pro Forma Combined Statement of Operations for the twelve -monthperiod ended June30, 2024 and under “ Accumulated Deficit” in the Unaudited Pro Forma Combined Statement of Financial Position as of December31, 2024. Additionally, considering that not all of APx’s estimated transaction expenses were recognized in its historical financial statements as of December31, 2024, this pro forma adjustment includes the recognition of a liability of $3.76million, considering that said amount is within the limit of “ SPAC Transaction Expenses” that will be assumed by OmnigenicsAI, provided for in the Business Combination Agreement. See Note (1) under “ Adjustments to Unaudited Pro Forma Combined Statement of Operations for the twelve -month period ended June 30, 2024 and the six -month period ended December 31, 2024.”

111 Finally, an effect of $58.15million was considered in Share premium (